SCHEMBL3345320

SCHEMBL3345320

CC1(C)CCC(NCc2ccc(-c3cccc(NC(=O)C(F)(F)F)c3)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PAX8 Q06710 2/20 0.47
MEN1 O00255 1/20 0.47
HSP90AA1 P07900 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM1A O60341 1/20 0.40
FGFR3 P22607 3/20 0.39
KDR P35968 3/20 0.39
ECE1 P42892 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
WNT3A P56704 3/20 0.38
HPGDS O60760 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
BRAF P15056 1/20 0.37
CHEK1 O14757 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
PRKD1 Q15139 1/20 0.35
CD274 Q9NZQ7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3345482 0.84 NPC1 (0.45) NPC1RAB9APAX8MEN1HSP90AA1
SCHEMBL3345300 0.83 NPC1 (0.42) NPC1RAB9APAX8MEN1HSP90AA1
Trifluoroacetic Acid SCHEMBL3345314 0.83 OPRM1 (0.45) KDM1AHPGDSEGLN1PRKD1CD274
SCHEMBL1345620 0.81 OPRM1 (0.49) KDM1AHPGDSEGLN1PRKD1CD274
SCHEMBL3345280 0.78 NPC1 (0.40) NPC1RAB9APAX8MEN1HSP90AA1
Trifluoroacetic Acid SCHEMBL16194671 0.71 PRKD1 (0.43) RAB9AMEN1KMT2APRKD1
SCHEMBL3339287 0.71 GRIA2 (0.46) NPC1RAB9APAX8MEN1HSP90AA1
Trifluoroacetic Acid SCHEMBL3340019 0.70 SLC2A1 (0.41) RAB9AMEN1KMT2APRKD1
SCHEMBL13137146 0.70 FLT3 (0.34) RAB9AMEN1KMT2APRKD1CD274
Trifluoroacetic Acid SCHEMBL3338278 0.70 OPRM1 (0.50) RAB9AMEN1KMT2AKDM1ACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 NPC1 3112/4885RAB9A 2340/4885PAX8 1560/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 NPC1 3467/4885RAB9A 1186/4885PAX8 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.